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Resource Utilization in Breast Cancer Survivors With and
Without Type 2 Diabetes
Susan Storey, PhD, AOCNS,1 Zuoyi Zhang, PhD,2 Xiao Luo, PhD,3 Megan Metzger, MS,4
Amrutha Ravali Jakka, PharmD, MS,3 Kun Huang, PhD,2 Diane Von Ah, PhD, RN1
1
3

Indiana University School of Nursing, Indianapolis, IN; 2Indiana University School of Medicine, Indianapolis, IN;
Indiana University School of Informatics and Computing, Indianapolis, IN; 4Regenstrief Institute, Indianapolis, IN

Purpose	Up to 74% of breast cancer survivors (BCS) have at least one preexisting comorbid condition, with
diabetes (type 2) common. The purpose of this study was to examine differences in health-related
outcomes (anemia, neutropenia, and infection) and utilization of health care resources (inpatient,
outpatient, and emergency visits) in BCS with and without diabetes.
Methods	In this retrospective cohort study, data were leveraged from the electronic health records of a large
health network linked to the Indiana State Cancer Registry. BCS diagnosed between January 2007
and December 2017 and who had received chemotherapy were included. Multivariable logistic
regression and generalized linear models were used to determine differences in health outcomes and
health care resources.
Results 	The cohort included 6851 BCS, of whom 1121 (16%) had a diagnosis of diabetes. BCS were, on
average, 55 (standard deviation: 11.88) years old, the majority self-reported race as White (90%), and
48.8% had stage II breast cancer. BCS with diabetes were significantly older (mean age of 60.6 [SD:
10.34] years) than those without diabetes and were often obese (66% had body mass index of ≥33).
BCS with diabetes had higher odds of anemia (odds ratio: 1.43; 95% CI: 1.04, 1.96) and infection
(odds ratio: 1.86; 95% CI: 1.35, 2.55) and utilized more outpatient resources (P<0.0001).
Conclusions	Diabetes has a deleterious effect on health-related outcomes and health care resource utilization
among BCS. These findings support the need for clinical practice guidelines to help clinicians manage
diabetes among BCS throughout the cancer trajectory and for coordinated models of care to reduce
high resource utilization. (J Patient Cent Res Rev. 2022;9:15-23.)
Keywords	breast cancer; survivorship; type 2 diabetes; health-related outcomes; electronic health records;
health care utilization

N

early three-fourths of breast cancer survivors
(BCS) have at least one preexisting comorbid
condition at the time of their cancer diagnosis.
Type 2 diabetes is one of the most common comorbid
conditions among BCS.1-3 Although the prevalence of
diabetes in the general U.S. population has been reported
to be 10.5%, prevalence of diabetes among BCS may be
as high as 33%.4,5 By 2030, the prevalence of diabetes
is expected to increase by 54%.6 Given that the 5-year
survival rates for BCS have increased to approximately
91%, it is likely that more BCS will also be living with
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diabetes,6 which may impact survivors’ health-related
outcomes and health care resource utilization.
A dual diagnosis of breast cancer and diabetes has the
potential to pose a significant burden on survivors
throughout the cancer trajectory. Adults with diabetes are
at risk of developing anemia, neutropenia, and infection.7-9
Metabolic and hormonal changes associated with breast
cancer diagnosis and treatment may further exacerbate
these outcomes,10,11 prompting increased utilization of
health care resources and, thus, medical expenditures.
Alone, a diagnosis of breast cancer or diabetes is
associated with substantial medical expenditures,12,13
with reports suggesting that breast cancer and diabetes
care in the United States may cost as much as $16.5
billion12 and $327 billion,13 respectively. Breast cancer,
in conjunction with diabetes, may have a significant
economic impact14 on both survivors and health systems.
aah.org/jpcrr
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Despite the high prevalence of diabetes among BCS, there
is a dearth of research examining differences in healthrelated outcomes and utilization of health care resources
between BCS with and without diabetes. Among BCS,
studies have examined the role of diabetes on prognosis,
survival, mortality, and quality of life, with little focus on its
influence on specific health-related outcomes or health care
utilization.15-17 We found only two studies that examined
these latter endpoints. In a large cohort (N=70,781) of
older BCS (≥65 years of age), Srokowski and colleagues
found that those with diabetes had greater odds of anemia,
neutropenia, infection, and hospitalization than those
without diabetes.4 More recently, Heo and colleagues
examined claims data to determine health care utilization
among BCS (majority in age range of 40–69 years)
with metabolic comorbidities (hypercholesterolemia,
hypertension, and diabetes mellitus) and found that BCS
with diabetes utilized more inpatient and outpatient
resources, indicating the complexity of care required
for this subgroup of BCS.10 However, these studies
failed to examine younger survivors4 and other potential
confounding factors (eg, demographic and clinical
characteristics) that may be related to outcomes.4,10

consisted of patients diagnosed with breast cancer
between January 2007 and December 2017 and who
were registered in the Indiana Network for Patient Care,
a unique health information infrastructure that includes
electronic clinical information from nearly every health
system statewide and is managed through the Regenstrief
Institute Data Core.25 The network is one of the United
States’ largest interorganizational data repositories. The
study was approved by Indiana University’s institutional
review board.

Demographic (eg, age and race) and clinical characteristics
(eg, body mass index [BMI], other comorbidities, and
smoking status) may influence health-related outcomes
and utilization of health care resources. For example,
those who are older or burdened by racial inequalities have
a higher propensity for poorer health-related outcomes
(eg, myelosuppression and infection) and increased
health care utilization.18-20 Other studies have shown that
BCS who have increased BMI or comorbidities other
than diabetes or who smoke are at increased risk for
poorer health-related outcomes and increased health care
utilization.16,21-24 Previous research has failed to consider
these confounding factors when exploring the impact of
diabetes on BCS. Therefore, the purpose of this study
was to examine differences in 1) health-related outcomes
(anemia, neutropenia, and infection) and 2) utilization of
health care resources (inpatient, outpatient, and emergency
visits) between BCS with and without diabetes, while
controlling for known covariates (age, racial disparities,
BMI, other comorbidities, and smoking status). Findings
may help clinicians identify high-risk survivor groups
and ultimately facilitate the development of interventions
directed toward improving health-related outcomes and
health care utilization among BCS with diabetes.

A total of 6851 individuals with breast cancer (identified
by ICD-9 code 174 and ICD-10 code C50) met inclusion
criteria and were included in the study cohort. Diabetes
status of the BCS also was determined by ICD-9/10 codes.
Demographics (age and race) and clinical characteristics
(BMI, comorbidities, smoking status, and cancer stage)
were extracted from the electronic health records. BMI
was categorized as <18.5, ≥18.5 to <25, ≥25 to <30, and
≥30 in the analysis. Charlson comorbidity score was used
to assess comorbid conditions; cancer and diabetes were
not included in the calculation of the score for this study.
Higher scores indicate more comorbidities and greater
disease burden.26

METHODS

Study Design

This was a retrospective cohort study that used electronic
health records from a large statewide health network
linked to the Indiana State Cancer Registry. The cohort
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Eligibility

Eligible BCS were 1) diagnosed with stage I–III breast
cancer, 2) treated with chemotherapy (neoadjuvant or
adjuvant) as part of their initial treatment, and 3) ≥21
years of age. BCS with preexisting diagnosis of type 2
diabetes prior to the breast cancer diagnosis as well as
those with no diagnosis of type 2 diabetes were included
in the study. BCS were not eligible for the study if they
had a history of another cancer, except basal or squamous
skin cancer, or if they were diagnosed with diabetes after
the breast cancer diagnosis.
Procedures

Health-related outcomes, including anemia, neutropenia,
and infection, were identified based on the ICD-9/10
codes. For the purpose of this study, we examined the
health-related outcomes that occurred within 1 year
following the start date of chemotherapy for breast
cancer. Data on the utilization of health care resources
were extracted from the electronic health records based
on documented encounters (number of visits) to inpatient,
outpatient, and emergency resources. For the purpose
of this study, we examined the utilization of resources
within 1 year following the start date of chemotherapy.
The accuracy of the dataset was verified by 1) repeating
the data extraction and comparing the results (number of
records and variables) with the original dataset and 2)
enlisting a review by a second data analyst of the data
code and the final dataset.
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Statistical Analysis

Descriptive statistics were used to describe the demographic
and clinical characteristics of the sample. Multivariable
logistic regression was performed to compare the healthrelated outcomes of BCS with and without diabetes.
Diabetes was the primary independent variable categorized
as a dichotomous variable (yes or no). Known confounding
factors, including age, race, BMI, comorbidities, and
smoking status, were controlled for in the regression
analyses. Analyses to evaluate the effect of neoadjuvant
chemotherapy and surgery type (eg, lumpectomy or
mastectomy surgery) on infection were performed. To
compare the utilization of health care resources among
BCS with and without diabetes, a generalized linear model
with Poisson distribution using a log-link function was
performed for each health care site (inpatient, outpatient,
and emergency visits). All analyses were performed using
SAS® 9.4 software (SAS Institute Inc.).

RESULTS

Table 1 displays the descriptive information of the total
sample and subgroups of BCS with and without diabetes.
The cohort included 6851 BCS, of whom 1121 (16%) had
a diagnosis of diabetes. BCS in the overall sample were,
on average, 55 years old, were predominantly White, and
primarily had stage II breast cancer. BCS with diabetes
were older and had higher BMI. Among the 6851 BCS,
3740 (55%) had lumpectomy or mastectomy surgery
before the initial chemotherapy and 3111 (45%) BCS had
no surgery before initial chemotherapy. No difference was
found in infection rates in BCS who received neoadjuvant
chemotherapy compared to BCS who did not (odds ratio
[OR]: 0.81, 95% CI: 0.63, 1.04; P=0.095). The effect of
surgery type (lumpectomy or mastectomy) on infection
was evaluated but was not significant in this sample
(OR: 0.84, 95% CI: 0.63, 1.11; P=0.22).

Table 1. Clinical Characteristics of Breast Cancer Survivors
BCS without
diabetes (n=5730)

BCS with
diabetes (n=1121)

All BCS
(N=6851)

P

Age, mean (SD)

54.12 (11.87)

60.63 (10.34)

55.18 (11.88)

<0.0001

Body mass index, mean (SD)

28.96 (6.68)

33.08 (7.92)

29.83 (7.16)

<0.0001

Comorbidities, mean (SD)

0.14 (0.45)

1.01 (1.19)

0.30 (0.73)

<0.0001

Race, n (%)
Black
White
Unknown

491 (8.71)
5147 (91.29)
92

183 (16.43)
931 (83.57)
7

674 (9.98)
6078 (90.02)
99

<0.0001

Body mass index, n (%)
Underweight
Normal
Overweight
Obese
Unknown

48 (2.40)
558 (27.93)
631 (31.58)
761 (38.09)
3732

13 (2.41)
71 (13.17)
99 (18.37)
356 (66.05)
582

61 (2.40)
629 (24.79)
730 (28.77)
1117 (44.03)
4314

<0.0001

Comorbidity index score, n (%)
0
1
≥2
Unknown

4408 (88.84)
451 (9.09)
103 (2.08)
768

442 (40.15)
393 (35.69)
266 (24.16)
20

4850 (79.99)
844 (13.92)
369 (6.09)
788

<0.0001

Smoking status, n (%)
Former
No
Current
Unknown

215 (7.68)
2226 (79.50)
359 (12.82)
2930

64 (10.21)
469 (74.80)
94 (14.99)
494

279 (8.14)
2695 (78.64)
453 (13.22)
3424

0.0261

Stage, n (%)
I
1771 (30.91)
II
2800 (48.87)
III
1159 (20.23)
BCS, breast cancer survivors; SD, standard deviation.

347 (30.95)
546 (48.71)
228 (20.34)

2118 (30.92)
3346 (48.84)
1387 (20.25)

0.9943

Variable
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Health-Related Outcomes

Table 2 displays the results of the multiple regression
analyses. BCS with diabetes had increased odds of
anemia than BCS without diabetes. Older BCS also had
higher odds of anemia than younger BCS. We did not find
higher odds for neutropenia among BCS with diabetes.
BCS with a comorbidity score of 1 had higher odds of
neutropenia than BCS with a comorbidity score of zero,
indicating that those with more comorbidities have higher
odds of neutropenia. BCS who smoked also had higher
odds for neutropenia than nonsmoking BCS.
BCS with diabetes had higher odds of infection than
those without diabetes. BCS who self-reported as White
(reference variable for race) had higher odds for infection
compared to BCS who self-reported as Black. BCS
who were overweight or obese also had higher odds
of infection than BCS with normal BMI. BCS with a
comorbidity score of ≥2 had higher odds of infection than

BCS with a comorbidity score of zero, indicating that
those BCS with more comorbidities had increased odds
of infection. Also, BCS who smoked had higher odds of
infection than nonsmoking BCS.
Health Care Resource Utilization

Table 3 shows the results of the Poisson regression model,
which depicts the number of inpatient, outpatient, and
emergency health care visits. There was no difference
noted between BCS with and without diabetes and the use
of inpatient or emergency room visits; however, BCS with
diabetes had a higher rate of outpatient visits than those
without diabetes. BCS of younger age or Black race had a
higher rate of all visit types than older-age or White BCS.
BCS who had a normal BMI had higher rate of inpatient
visits than overweight BCS, whereas the BMI categories
of underweight or overweight had higher rate of outpatient
visits than BCS of normal or obese weight. BCS with a

Table 2. Logistic Regression of Health-Related Outcomes (Anemia, Neutropenia, and Infection)
Anemia
(n=283)

Neutropenia
(n=824)

Infection
(n=273)

Variable

OR

95% CI

OR

95% CI

OR

95% CI

Diabetes
Yes
No

1.43
Ref

1.04, 1.96

1.19
Ref

0.96, 1.48

1.86
Ref

1.35, 2.55

Age

1.02

1.01, 1.03

0.99

0.99, 1.00

1

0.99, 1.01

Race
Black
Unknown
White

1.07
2.08
Ref

0.73, 1.56
0.92, 4.72

0.89
1.09
Ref

0.69, 1.13
0.59, 2.02

0.49
0.72
Ref

0.31, 0.77
0.20, 2.59

Body mass index
Underweight
Overweight
Obese
Unknown
Normal

2.04
1.36
1.25
0.93
Ref

0.84, 4.93
0.87, 2.13
0.82, 1.91
0.61, 1.41

0.05
0.93
0.94
1.33
Ref

0.00, 0.76
0.71, 1.23
0.72, 1.21
1.04, 1.69

1.05
1.8
1.78
0.88
Ref

0.33, 3.28
1.14, 2.82
1.16, 2.75
0.56, 1.39

Comorbidity index score
1
≥2
Unknown
0

1.19
1.34
0.64
Ref

0.83, 1.69
0.85, 2.11
0.38, 1.09

1.26
1.31
0.42
Ref

1.00, 1.59
0.95, 1.81
0.29, 0.59

1.11
1.77
0.45
Ref

0.77, 1.61
1.15, 2.73
0.23, 0.86

Smoking status
Former
Unknown
Current
No

1.35
1.09
1.15
Ref

0.85, 2.13
0.82, 1.44
0.72, 1.84

1.00
0.60
1.60
Ref

0.72, 1.39
0.50, 0.71
1.23, 2.07

0.84
0.74
1.84
Ref

0.51, 1.39
0.55, 1.00
1.26, 2.67

OR, odds ratio; Ref, reference variable.
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comorbidity score of ≥2, indicating higher comorbidities,
had significantly more inpatient visits than BCS with
lower comorbidity scores; those with a comorbidity score
of 1 or ≥2 had fewer outpatient and emergency visits than
those with a comorbidity score of zero. Lastly, BCS who
smoke had more outpatient and emergency visits than
BCS who did not smoke.

DISCUSSION

To our knowledge, this is the first study to comprehensively
examine health-related outcomes and utilization of health
care resources in BCS with and without type 2 diabetes.
Our large cohort study yielded several important findings.
First, 16% of BCS had diabetes, which is comparable to
other studies reporting 11%–33%.1,4,17 Second, BCS with
diabetes had higher odds of anemia and infection compared
to their counterparts. Lastly, BCS with diabetes utilized
more outpatient resources than BCS without diabetes.
These findings indicate the need to coordinate cancer care
and diabetes care throughout the cancer trajectory.

Health-Related Outcomes

The presence of both breast cancer and diabetes can
cause myelosuppression resulting in anemia and
neutropenia.7,27,28 Researchers have estimated that 41%–
82% of BCS experience anemia.28 Among women with
diabetes but no cancer, approximately 39% experience
anemia.8 However, these studies did not include women
with both breast cancer and diabetes, and thus, the
true estimate for the prevalence of anemia among both
diseases is largely unknown. We found only one study
that examined the effect of diabetes on anemia in BCS.4
Similar to our study’s findings, the researchers found that
older BCS with diabetes were 1.24 times more likely
to have anemia than BCS without diabetes.4 Although
more studies are needed, BCS with diabetes may be
at a greater risk for anemia. Not surprisingly, we also
found that older BCS had increased odds of anemia
than younger BCS, as older BCS are more susceptible to
myelosuppression.7

Table 3. Poisson Regression of Health Care Resource Utilization (Emergency, Inpatient, and Outpatient Visits)
Inpatient (n=2469)

Outpatient (n=6098)

Emergency (n=2104)

Variable

Estimate (95% CI)

P

Estimate (95% CI)

P

Estimate (95% CI)

P

Diabetes
Yes
No

0.05 (-0.03, 0.12)
Ref

0.2261

0.16 (0.15, 0.18)
Ref

<0.0001

0.06 (-0.03, 0.14)
Ref

0.2087

-0.004 (-0.007, -0.002)

0.0001

-0.006 (-0.006, -0.005)

<0.0001

-0.007 (-0.010, -0.004)

<0.0001

Race
Black
Unknown
White

0.18 (0.11, 0.26)
-0.29 (-0.54, -0.04)
Ref

<0.0001
0.0244

0.05 (0.03, 0.06)
0.13 (0.09, 0.16)
Ref

<0.0001
<0.0001

0.18 (0.10, 0.26)
-0.12 (-0.41, 0.17)
Ref

<0.0001
0.4172

Body mass index
Underweight
Overweight
Obese
Unknown
Normal

-0.05 (-0.34, 0.23)
-0.17 (-0.28, -0.05)
-0.002 (-0.10, 0.10)
0.24 (0.14, 0.33)
Ref

0.7102
0.0063
0.9736
<0.0001

0.16 (0.12, 0.20)
0.06 (0.05, 0.08)
-0.0002 (-0.02, 0.02)
-0.22 (-0.24, -0.21)
Ref

<0.0001
<0.0001
0.9781
<0.0001

-0.04 (-0.31, 0.23)
-0.09 (-0.21, 0.03)
0.01 (-0.10, 0.11)
-0.09 (-0.19, 0.01)
Ref

0.7649
0.1449
0.9157
0.0814

CCI score
1
≥2
Unknown
0

-0.08 (-0.16, 0.01)
0.13 (0.02, 0.23)
-0.08 (-0.19, 0.03)
Ref

0.0720
0.0184
0.1556

-0.03 (-0.04, -0.01)
-0.06 (-0.08, -0.03)
-0.43 (-0.45, -0.41)
Ref

0.0003
<0.0001
<0.0001

0.13 (0.04, 0.22)
0.36 (0.25, 0.48)
-0.21 (-0.38, -0.04)
Ref

0.0041
<0.0001
0.0141

Smoking status
Former
Unknown
Current
No

-0.12 (-0.27, 0.03)
-0.01 (-0.07, 0.04)
0.05 (-0.05, 0.16)
Ref

0.1224
0.6441
0.3249

-0.01 (-0.03, 0.01)
-0.02 (-0.04, -0.01)
0.02 (0.00, 0.04)
Ref

0.4177
<0.0001
0.0116

-0.19 (-0.35, -0.02)
0.06 (-0.01, 0.13)
0.11 (0.01, 0.21)
Ref

0.0307
0.1022
0.0348

Age

CCI, Charlson Comorbidity Index; Ref, reference variable.
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Diabetes status did not significantly increase the odds
of neutropenia among BCS in our study. This contrasts
to a previous large cohort study, which found that older
(≥65 years) diabetic BCS had 1.2 increased odds of
developing neutropenia;4 however, that study’s older
population may have led to the more pronounced
finding. In adult BCS of all ages, we found that those
with more comorbidities (score of 1 or more) and those
who smoked had higher odds for neutropenia, indicating
the complexity of caring for patients with multiple
comorbidities and the need for ongoing support for
tobacco cessation.
Although we did not find that BCS with diabetes had
greater odds for neutropenia, they did show increased
odds of having an infection than BCS without diabetes.
These results support the few previous studies in this
area.4,29 In a study of 70,781 BCS, researchers found those
with diabetes had higher odds of developing an infection
(OR: 1.43, 95% CI: 1.20, 1.70).4 In another large study
of BCS (n=7865), researchers found BCS with diabetes
experienced pneumonia (15.0% vs 13.1%; P<0.001) and
sepsis (8.6% vs 7.2%; P<0.001) infections more than
BCS without diabetes.29 Investigators hypothesized that
diabetes and associated hyperglycemia might attenuate
the immune system through impaired migration,
phagocytosis, and chemotaxis, thereby increasing
vulnerability to infection.9,30
Demographic and clinical characteristics also were
important to health-related outcomes in BCS. We
found that being overweight or obese was associated
with increased odds of infection. BMI has been shown
to increase the risk of getting an infection due to its
diminishing effects on immune surveillance and the
structure and function of inflammatory mediators.31
Comorbidities were associated with increased odds
of neutropenia and infection. Additionally, BCS
who smoke had higher odds for infection. Smoking
has been shown to decrease immune function and
increase inflammatory biomarkers that contribute
to the risk of infections.32 Among BCS, researchers
have noted smoking to be a risk factor for surgical
site infections (OR: 2.1, 95% CI: 0.9, 4.9).33 Our
findings emphasize the complexity of the intersection
of multiple comorbidities (cancer, diabetes) and other
health indicators (BMI, smoking) on health outcomes.
Future prospective studies are needed to confirm these
findings and examine the role of blood glucose (ie,
hyperglycemia) on these outcomes. This information
can help clinicians identify subgroups at high risk for
myelosuppression and facilitate preemptive strategies to
mitigate these nefarious outcomes.
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Health Care Resource Utilization

Our study adds preliminary evidence that BCS with
diabetes utilize more health care resources. Unlike other
studies that have shown that BCS with diabetes were more
likely to utilize inpatient and emergency room services,4,10
we found that BCS with diabetes utilized more outpatient
visits than BCS without diabetes. Other researchers have
suggested that diabetes care is often reprioritized once the
cancer diagnosis is received, and hence, cancer survivors
with diabetes are less likely to see their primary care
doctor for diabetes-related care concerns during active
treatment.34,35 It is possible that BCS with diabetes in this
sample were utilizing more resources for cancer-related
issues and that diabetes management was deferred to
their oncologists rather than primary care providers
or diabetes specialists. However, we did not evaluate
the reason for the outpatient visit or do a chart review
to determine the cause or type of visit. More research
examining the cause for visit and the type of practitioner
utilized is needed to fully understand patterns of resource
utilization. Despite this limitation, there is a growing
need to address the clinical management of cancer
survivors with diabetes; it is a significant challenge, one
that will require interdisciplinary collaboration between
oncologists, endocrinologists, nurses, dieticians, cancer
survivors, and their caregivers.36
Demographic factors were related to the utilization of
health care resources. Younger BCS had more visits to all
three services (inpatient, outpatient, and emergency) than
older BCS. Unlike older BCS, younger BCS have greater
difficulty adjusting after treatment, report and incur more
symptoms, and report poorer quality of life,37,38 which
may impact the utilization of resources. Additionally, we
found that Black BCS had more inpatient, outpatient, and
emergency visits. Higher use of emergency services may
be the primary access point utilized to access the health
system, resulting in increased hospital admissions due to
severity of illness. Higher utilization of outpatient and
inpatient services may be indicative of exacerbated illness
requiring more specialized care. While an indication that
more research is needed to examine the management of
chronic disease among Black BCS, this finding is limited
by the small number of Black patients in our study
sample. More racially representative studies are needed
to confirm this finding.
Clinical characteristics also may play a role in the
utilization of health care. For instance, BMI influenced
the utilization of resources in unique ways. First,
we found that BCS with normal BMI utilized more
inpatient services than overweight BCS. However,
this finding may be influenced by the low number of
BCS in our study in the normal BMI category. Second,
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overweight BCS had more outpatient visits. Similar
findings regarding the deleterious effect of BMI on
health care utilization have been noted in other studies.23
Being overweight has been associated with a greater
likelihood of developing comorbid conditions, which
requires more outpatient care to manage.23 Third,
underweight BCS had more outpatient visits than BCS
of normal weight. Being underweight may reflect poor
nutritional status and/or chemotherapy side effects, such
as cachexia, nausea, and vomiting, all of which could
contribute to an increase in outpatient visits. Further
research is warranted to examine the influence of low
BMI on health care utilization.
In our study, a higher comorbidity score was associated
with increased health care utilization, indicating that
comorbidities other than diabetes factor into utilization.
Among cancer survivors, comorbidities have been
associated with increased use of inpatient, outpatient,
and emergency services, resulting in higher health care
costs.39 Cancer survivors with comorbidities represent
a complex population. Primary care providers and
oncologists play an integral role in managing the
complex interplay of cancer, comorbid conditions,
and health care resources. Cancer treatment and
survivorship plans should address these complexities
and facilitate collaboration between primary care,
oncology, and other medical specialties to deliver
individualized disease management. Future research
should identify cancer survivors at high risk and
strategies to mitigate the impact of these comorbidities
on clinical outcomes and health care utilization. BCS
who smoked had more outpatient and emergency
visits. Smokers often have other chronic conditions
requiring health care resources.40 High utilization of
inpatient, outpatient, and emergency resources is costly
and indicative of the need for better coordination of
care among the health care team to maximize disease
treatment, attenuate health care expenses, and improve
the quality of life of BCS.
As BCS are living longer due to advances in treatment,
it is important that we understand the impact of
comorbidities, especially diabetes, on health-related
outcomes and subsequent utilization of health care
resources. The increased health care utilization among
BCS with diabetes has potentially significant economic
implications. Given that many survivors are of working
age, having both breast cancer and diabetes can reduce
work productivity, increase disability, and contribute
substantially to the economic burden of survivors.12,41-43
As these outcomes are potentially preventable, there
is a clear need to improve the integration of cancer
treatment with the ongoing delivery of diabetes care.

Original Research

With coordinated care models, the economic burden on
both BCS and the health system may decrease.
Strengths and Limitations

A major strength of this study is the large populationbased cohort of BCS. Additionally, the use of electronic
health records to examine the impact of diabetes on
health-related outcomes and health care utilization
allowed for the analysis of large volumes of real-world
data. With big data, knowledge can be generated that has
the potential to improve care and health-related outcomes
as well as reduce associated costs.
Findings should be considered in the context of our
study’s limitations. The descriptive, retrospective
design precludes the ability to interpret causality.
Although we used ICD-9/10 codes to examine healthrelated outcomes, it is possible some cases of anemia,
neutropenia, and infection were not coded and
therefore not included in the analysis. Additionally, the
majority of BCS in the study were White, limiting the
generalizability of the findings. While important factors
in the treatment of breast cancer, we did not extract
specifics regarding tumor subtypes or chemotherapy
regimens from the data source. Lastly, we were unable
to ascertain the specific types of health care services and
providers accessed, any new diagnoses associated with
resource utilization, or whether health care resources
were accessed from outside the 5 hospital systems that
contribute to the data repository. Future research should
examine the diagnoses associated with health care
resources and the types of practitioner services used
among BCS with diabetes.
Despite these limitations, this study provides preliminary
data that may be useful for guiding the development of
future prospective studies. Given that the prevalence of
diabetes is increasing, prospective studies exploring the
differences in health-related outcomes and health care
resource utilization among other cancer survivor groups
with diabetes are needed.

CONCLUSIONS

This innovative study demonstrated that comorbid type
2 diabetes deleteriously affects health-related outcomes
and health care resource utilization among breast cancer
survivors. These findings suggest the need for clinical
practice guidelines to help clinicians manage diabetes
among BCS throughout the cancer trajectory and
coordinated models of care to reduce the high utilization
of health care resources. More studies are needed to
explore the ramifications of diabetes in BCS and to
develop and test interventions to improve outcomes and
decrease resource utilization.
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Patient-Friendly Recap
•P
 atients successfully treated for cancer may
encounter more difficulty in managing other
diseases such as diabetes.
• Authors in Indiana reviewed health records for
a statewide cohort of breast cancer survivors to
determine the effects a diagnosis of type 2 diabetes
had on patient outcomes and health care utilization.
•D
 iabetic survivors had higher rates of anemia and
infection, and significantly more outpatient clinical
visits, than those without diabetes.
• As advances in cancer treatment further extend
lifespans, providers need updated and resourcecognizant models of care to better manage the
comorbidities likely to become more commonly
seen in this patient population.
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